Morquio Syndrome Treatment Market Size, Share, Growth Analysis, By Treatment(Enzyme Replacement Therapy, Other.), By Disease Type(Morquio A, Morquio B), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031

Morquio Syndrome Treatment Market size was valued at USD 87.52 million in 2019 and is poised to grow from USD 95.72 million in 2023 to USD 188.57 million by 2031, growing at a CAGR of 9.54% in the forecast period (2024-2031).

In addition to recent regulatory approvals, there has been an increase in R&D for the treatment of Morquio syndrome, as shown by the increased inclusion of the condition in the clinical pipelines of the leading market participants. For the Morquio syndrome, for instance, Shire is conducting a Phase 3 Study, Ultragenyx Pharmaceutical Inc. is testing a medicine (AGT 181) in a clinical trial, and ArmaGen, Inc. is also testing a treatment for the syndrome in young patients. The market for treatments for Morquio syndrome is expanding as a result of this as well as increased disease awareness. 'BioMarin Pharmaceutical Inc.', 'Shire (now part of Takeda Pharmaceutical Company Limited)', 'Ultragenyx Pharmaceutical Inc.', 'Abeona Therapeutics Inc.', 'RegenxBio Inc.', 'Sangamo Therapeutics Inc.', 'REGENXBIO Inc.', 'ArmaGen Inc.', 'Lysogene S.A.', 'Zymenex A/S', 'Spark Therapeutics (now part of Roche)', 'Orchard Therapeutics plc', 'Idorsia Pharmaceuticals Ltd.', 'JCR Pharmaceuticals Co., Ltd.', 'SOBI (Swedish Orphan Biovitrum AB)', 'Green Cross Corporation', 'Cabaletta Bio Inc.', 'Audentes Therapeutics (now part of Astellas Pharma Inc.)', 'Aeglea BioTherapeutics', 'Krystal Biotech Inc.'

It is projected that the market for treatments for Morquio syndrome would expand at a very rapid rate due to the increase in the number of products in the early and advanced stages of R&D as well as the focus on treating rare diseases. Several medications that are now in the pipelines of various firms can be predicted to undergo regulatory approvals for the marketing, if they have positive clinical trial results, as a result of the recent approval of the elosulfase alfa (VIMIZIM) drug.

As demonstrated by the increased inclusion of the illness in the clinical pipelines of the key market participants, there has been increased activity in R&D for the treatment of Morquio syndrome in addition to the most recent regulatory approvals. Examples include a Phase 3 Study being conducted by Ultragenyx Pharmaceutical Inc. for the Morquio syndrome, a clinical trial being conducted by the Shire for children with the syndrome, and a medication (AGT 181) being tested in clinical trials by ArmaGen, Inc. This, along with the increased public knowledge of the condition, is also fueling the market for treatments for Morquio syndrome.

The Asia Pacific is also expected to dominate the market over the forecast period owing to factors such as the rising disposable income of individuals and increasing demand for passenger cars with advanced technology from the developing countries.